Drug Testing Integrity

More documents

Recommendations

Info

Rep. Bart Stupak (D-Mich.) bemoans the Whizzinator while holding an advertisement for the device. At left is Ed Whitfield (R-Ky.), the subcommittee chairman. Photo Credit: By Robert A. Reeder -- The Washington Post 10
• “The sheer number of these products, and the ease with which they are marketed and distributed through the Internet, present formidable obstacles to the integrity of the drug testing process.” ◦ GAO-05-653T: “<strong>Drug</strong> Tests: Products to Defraud <strong>Drug</strong> Use Screening Tests Are Widely Available.” 11
Page 1 and 2: Opioid Risk Management June 26-27,
Page 3 and 4: 1. Eliminate the evidence - substit
Page 5 and 6: • Death Investigations • Crimin
Page 7 and 8: ◦ Lab profits are based on rapid
Page 9: • The media breakout product for
Page 15 and 16: $49.95 ORDER NOW! •Contains every
Page 17 and 18: • High-Tech Meets Low-Tech The Th
Page 21 and 22: in vitro Adulterants Available Comm
Page 25 and 26: Chromium: Conclusions and Interpret
Page 29 and 30: Strategies to Manage the Integrity
Page 31 and 32: • Policy Considerations ◦ Make
Page 33 and 34: • Gown patient • Observed colle
Page 35 and 36: The effects of adulterants and sele
Page 37: • How do you manage positive test

Drug Testing Integrity

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?